| HOME >> MEDICINE >> TECHNOLOGY |
The CGI-I scale is a standard assessment used to rate the severity of a patient's illness and improvement over time.
The PGA is a scale that measures overall improvement as assessed by parents.
DAYTRANA(TM) is a trademark of Shire Pharmaceuticals Ireland Limited.
Important Safety Information
Tell your doctor about any heart conditions, including structural abnormalities, your child or a family member may have. Inform your doctor immediately if the child develops symptoms that suggest heart problems, such as chest pain or fainting.
DAYTRANA should not be used if the child has: significant anxiety, tension, or agitation; allergies to methylphenidate or other ingredients of DAYTRANA; glaucoma; discontinued in the last 14 days or is taking a monoamine oxidase inhibitor (MAOI); tics, or family history or diagnosis of Tourette's syndrome.
Tell your doctor before using DAYTRANA if the child: is being treated for or has symptoms of depression (e.g. sadness, worthlessness or hopelessness) or bipolar disorder; has family history of tics; has abnormal thoughts or visions, hears abnormal sounds or has been diagnosed with psychosis; has had seizures or abnormal EEGs; has or has had high blood pressure; exhibits aggressive behavior or hostility. Tell your doctor immediately if the child develops any of these conditions/symptoms while using DAYTRANA.
In clinical studies, side effects were generally mild to moderate. The most common side effects reported with DAYTRANA were decreased appetite, sleeplessness, sadness/crying, twitching, weight loss, nausea, vomiting, tics and affect lability (mood swings). Aggression, new abnormal thoughts/behaviors, mania and growth suppression have been associated with use of drugs of this type. Tell your doctor if the child has blurred vision while using DAYTRANA.
Abuse of DAYTRANA can lead to dependence.
'/>"/>
| SOURCE Shire plc Copyright©2008 PR Newswire. All rights reserved |